Mirador Therapeutics licenses long-acting KP-301 antibody from Kira Pharmaceuticals to enter ANCA-associated vasculitis

Mirador Therapeutics, Inc. has secured exclusive worldwide rights from Kira Pharmaceuticals to develop, manufacture and commercialize KP-301, a preclinical long-acting anti-C5a antibody intended for inflammatory vascular diseases. The company plans to begin a Phase 1 study by the end of 2026, followed by a Phase 2 trial in ANCA-associated vasculitis during the first half of 2027. The deal matters because the C5a pathway has attracted meaningful clinical and commercial interest, while the leading approved therapy targeting that pathway is now facing significant regulatory and data-integrity scrutiny. Mirador is betting that antibody engineering can provide durable C5a inhibition with less frequent administration and a differentiated safety profile. The central challenge is that KP-301 has not yet produced human data, leaving its dosing, tolerability and clinical value unproven.

What rights and financial obligations does Mirador receive under the Kira licensing agreement?

Mirador receives exclusive worldwide rights to develop, manufacture and commercialize KP-301 across all indications, together with related intellectual property. Kira will receive $12 million upon signing and could collect additional development and sales milestone payments.

The companies did not disclose the total potential value of those milestones, individual payment triggers or any royalty arrangements. This limits the ability to determine Mirador’s complete financial exposure if KP-301 progresses successfully.

The $12 million payment also requires careful interpretation. Mirador’s announcement focuses on KP-301 and attributes the signing payment to that agreement. However, a separate announcement connected with Jasper Therapeutics, Inc.’s acquisition of Kira says the broader out-licensing package also includes KP-402, a small-molecule C5a receptor antagonist.

That means the $12 million should be viewed as consideration for a complement asset package rather than as a clean valuation of KP-301 alone. The additional programme could give Mirador another way to target the same biological pathway, although the company has not provided a development plan for KP-402.

The licensing transaction was announced alongside Jasper’s all-stock acquisition of Kira and a planned $132 million private placement. Mirador was also identified as a participant in that financing. For the combined Jasper and Kira business, transferring KP-301 and KP-402 brings in non-dilutive capital while allowing resources to be concentrated on retained programmes such as KP-104, briquilimab and KP-701.

How is KP-301 designed to sustain C5a inhibition with less frequent chronic dosing?

C5a is an inflammatory protein generated by the complement system, a component of the body’s immune defence. When C5a binds to its receptor on immune cells, particularly neutrophils, it can amplify inflammation and contribute to vascular and tissue damage.

KP-301 is designed to bind C5a itself, preventing the protein from activating the C5a receptor. This differs from small-molecule therapies such as avacopan, which bind to the receptor rather than neutralizing the C5a ligand.

The antibody incorporates pH-dependent target binding and antibody-recycling technology. In principle, KP-301 binds C5a in circulation, carries the target into cells and releases it under the acidic conditions found inside cellular compartments. The antibody can then be recycled and returned to circulation, where it may bind additional C5a molecules.

This process is commonly described as a sweeping mechanism. It is intended to address the high and continuously replenished target burden that can otherwise consume an antibody and shorten its effective dosing interval.

Mirador believes the design could maintain C5a inhibition using relatively low and infrequent doses. That would be strategically valuable in chronic diseases, where treatment convenience can affect adherence, persistence and commercial adoption.

Those advantages remain design objectives rather than demonstrated clinical characteristics. Mirador has not disclosed KP-301’s intended route of administration, anticipated dosing interval, manufacturing profile or supporting human pharmacokinetic data. Phase 1 testing will therefore be the first major test of whether the antibody’s engineering translates into durable target coverage in people.

Why is ANCA-associated vasculitis the first Phase 2 target for Mirador’s KP-301 programme?

ANCA-associated vasculitis is a group of rare autoimmune diseases in which inflammation damages small blood vessels. The condition can affect the kidneys, lungs and other organs, creating a risk of severe and sometimes irreversible injury.

The biological rationale for targeting C5a is based on its role in activating and attracting neutrophils. In ANCA-associated vasculitis, these immune cells can become excessively activated and damage vessel walls. Interrupting the C5a signalling loop may reduce that inflammatory response without suppressing every function of the complement system.

The indication offers Mirador an established development pathway and clinically recognized biomarkers, but it is not an easy initial test. Trials must account for disease subtype, organ involvement, previous treatment, background immunosuppression and the use of glucocorticoids. Recruitment can also be difficult because the eligible population is relatively small and patients may present with urgent treatment needs.

Mirador intends to study KP-301 in both monotherapy and combination settings, with possible expansion into other inflammatory diseases. The company has not identified those additional indications or explained whether patient selection will depend on complement biomarkers generated through its Mirador360 precision-development platform.

Starting Phase 2 in the first half of 2027 would represent a rapid transition from licensing to clinical proof of concept. Meeting that timeline will depend on regulatory clearance, manufacturing readiness and a Phase 1 profile that supports chronic dosing.

How does KP-301 differ from the existing C5a pathway therapy used in vasculitis?

The principal commercial reference point is Tavneos, or avacopan, an oral C5a receptor antagonist developed by ChemoCentryx and acquired by Amgen. The drug received US approval in 2021 as an adjunctive treatment for adults with severe active ANCA-associated vasculitis in combination with standard therapy, including glucocorticoids.

Tavneos demonstrated that physicians and payers were willing to adopt a C5a pathway therapy. Amgen reported approximately $459 million in Tavneos sales during 2025 and another $119 million in the first quarter of 2026.

Its regulatory position has since become uncertain. In April 2026, the US Food and Drug Administration proposed withdrawing the approval after concluding that previously undisclosed changes to endpoint assessments undermined the evidence supporting effectiveness. The European Medicines Agency subsequently recommended revoking the drug’s European marketing authorization, and the New England Journal of Medicine retracted the publication describing its pivotal trial.

The FDA has separately warned about serious postmarketing liver injuries associated with avacopan, including fatal cases. Tavneos remains available in the United States while the withdrawal process and the sponsor’s requested hearing proceed.

This creates both an opportunity and a higher evidentiary burden for Mirador. KP-301 is a different molecule with a different modality, so concerns associated with avacopan cannot automatically be applied to it. Equally, an antibody mechanism does not establish superior safety without comparative clinical evidence.

Mirador will need trials capable of demonstrating that KP-301 provides reliable disease control, an acceptable safety profile and a practical dosing advantage. In the current regulatory environment, transparent endpoint adjudication, trial conduct and data handling will be particularly important.

How does the Kira license fit Mirador Therapeutics’ broader precision immunology strategy?

Mirador launched in March 2024 and has raised more than $650 million, including a $250 million Series B financing completed during the third quarter of 2025. The company is advancing clinical-stage programmes across Crohn’s disease, ulcerative colitis, rheumatoid arthritis and idiopathic pulmonary fibrosis.

It expects at least 10 clinical readouts across its portfolio by the end of 2027. Adding KP-301 expands that portfolio into inflammatory vascular disease while giving Mirador another programme with a defined near-term clinical schedule.

The company says its Mirador360 platform draws on more than 2.5 million molecular profiles from immune-mediated diseases. It uses those data to support target validation, indication selection, patient stratification and potential combination strategies.

KP-301 will test whether that platform can add value after an external asset has been licensed. The important output will not be the size of the underlying dataset, but whether Mirador can identify the patients most dependent on C5a signalling and design trials that produce a clear efficacy signal.

The transaction also reflects a broader portfolio-building model. Mirador is combining internal precision-development capabilities with acquired or licensed therapeutic candidates, allowing it to expand faster than a company dependent exclusively on internal discovery.

What must Phase 1 establish before Mirador can begin its planned 2027 AAV trial?

The Phase 1 programme must first determine whether KP-301 can be administered safely and predictably. Investigators will need to evaluate adverse events, immunogenicity, pharmacokinetics and the relationship between dose and C5a pathway inhibition.

The study must also show whether the sweeping mechanism produces the prolonged exposure and target coverage claimed by its design. If KP-301 requires frequent administration despite its engineering, one of the programme’s main sources of differentiation would weaken.

Mirador will need to select a dose that balances sustained pathway inhibition with tolerability and development cost. The company must also determine whether healthy-volunteer data are sufficient or whether early patient cohorts will be required to understand the effects of elevated C5a production during active disease.

A successful Phase 1 outcome would not demonstrate clinical efficacy in vasculitis. It would provide the dosing and safety foundation needed to conduct that test. Conversely, unexpected immunogenicity, insufficient target suppression or an impractical dosing requirement could delay or reshape the Phase 2 plan.

Which milestones will determine whether KP-301 becomes a differentiated complement therapy?

The first milestone is the initiation of Phase 1 testing by year-end 2026. Investors and potential partners should watch whether Mirador discloses the administration route, dose-escalation structure, population and pharmacodynamic measurements.

The next important disclosure will be the selected dosing interval. A genuinely infrequent regimen could distinguish KP-301 from a twice-daily oral therapy, although an injectable antibody must offer enough convenience and efficacy to offset the appeal of oral dosing.

Beginning the AAV Phase 2 trial during the first half of 2027 would demonstrate operational speed, but trial design will matter more than the calendar. Key questions include whether KP-301 is evaluated alongside standard immunosuppression, whether glucocorticoid reduction is measured and how remission, relapse and organ outcomes are adjudicated.

Longer term, Mirador must identify additional diseases in which C5a is a central driver rather than a secondary marker of inflammation. Expansion based only on biological plausibility could consume capital without generating decisive evidence.

The license gives Mirador a credible entry into complement-mediated vascular disease at a modest disclosed upfront cost. It does not yet establish that KP-301 is safer, more effective or more convenient than existing approaches. Those claims will depend on human evidence, and the first meaningful answers should begin arriving over the next 12 to 18 months.

What are the key takeaways from Mirador Therapeutics’ KP-301 licensing agreement?

• Mirador received exclusive worldwide rights to develop, manufacture and commercialize KP-301 across all indications.
• KP-301 is a preclinical anti-C5a antibody engineered for prolonged target coverage and potentially infrequent dosing.
• Mirador plans to begin Phase 1 testing by the end of 2026 and an AAV Phase 2 study during the first half of 2027.
• Kira will receive $12 million upfront and undisclosed development and sales milestone payments.
• Jasper’s transaction announcement indicates that the $12 million package also includes KP-402, so the payment cannot be attributed solely to KP-301.
• The antibody binds the C5a ligand, while avacopan blocks the C5a receptor.
• Regulatory and safety scrutiny surrounding Tavneos creates an opportunity for a new therapy but raises the evidence required to establish differentiation.
• KP-301 has no disclosed human safety, dosing or efficacy data.
• The transaction expands Mirador’s portfolio into inflammatory vascular disease and complements programmes in gastrointestinal, rheumatologic and fibrotic diseases.
• Phase 1 pharmacokinetics, target coverage, immunogenicity and dosing frequency will determine whether the antibody’s engineering provides a meaningful advantage.